Short answer
Emergent BioSolutions Inc. (EBS) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results for quarter ended March 31, 2026.
Emergent BioSolutions Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1 contains financial and operating details
- Results announcement dated April 30, 2026 and furnished under Item 2.02
Item 7.01 · Regulation FD Disclosure
- Earnings call scheduled for April 30, 2026, covering quarter ended March 31, 2026
- Earnings Call Slides furnished as Exhibit 99.2 and posted on Emergent BioSolutions’ website
- Disclosure provides investor access to management’s quarterly results presentation
- Items 2.02 and 7.01 materials not deemed filed under Exchange Act Section 18ETwitter
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $156.1M, down 30%; decline concentrated in Smallpox MCM down 40% and Anthrax MCM down 55%
- Net income $6.8M versus $68.0M; adjusted EBITDA $35.6M, down 55%, reflecting materially weaker operating earnings
- Commercial Products margin fell to 16% from 25%; unfavorable OTC NARCAN price-volume mix pressures profitability
- 2026 adjusted EBITDA forecast raised to $155M-$175M from $135M-$155M; revenue forecast unchanged at $720M-$760M
- Debt refinancing and new manufacturing partnerships improve flexibility, but government purchase timing remains a major revenue volatility risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Emergent BioSolutions Inc. 8-K filings
Get the next EBS 8-K as it lands
Follow EBS for push alerts, or ask the research agent what this filing means.